Dev Prasad
Stock Analyst at Lucid Capital
(4.67)
# 812
Out of 5,043 analysts
21
Total ratings
65%
Success rate
61.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dev Prasad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TTRX Turn Therapeutics | Initiated Coverage: Buy | $24 | $12.00 | +100.00% | 1 | Sep 24, 2026 | |
| GNLX Genelux | Initiated Coverage: Buy | $18 | $2.56 | +603.13% | 1 | Sep 16, 2026 | |
| FTH Faeth Therapeutics | Initiated Coverage: Buy | $59 | $26.03 | +126.66% | 1 | Sep 14, 2026 | |
| ANL Adlai Nortye Group | Initiated Coverage: Buy | $49 | $15.62 | +213.70% | 1 | Sep 8, 2026 | |
| ELOX Eloxx Pharmaceuticals | Initiated Coverage: Buy | $38 | $13.74 | +176.56% | 1 | Aug 20, 2026 | |
| PLYX Polaryx Therapeutics | Initiated Coverage: Buy | $7 | $2.00 | +250.00% | 1 | Jul 27, 2026 | |
| QNRX Quoin Pharmaceuticals | Initiated Coverage: Buy | $30 | $4.50 | +566.67% | 1 | May 4, 2026 | |
| ABOS Acumen Pharmaceuticals | Initiated Coverage: Buy | $6 | $2.14 | +180.37% | 1 | Dec 17, 2025 | |
| PVLA Palvella Therapeutics | Reiterated: Buy | $49 → $212 | $138.77 | +52.77% | 2 | Dec 15, 2025 | |
| IFRX InflaRx | Reiterated: Buy | $24 | $1.60 | +1,400.00% | 1 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $19 | $4.11 | +362.29% | 1 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $4.00 | $0.44 | +819.54% | 1 | Oct 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $1 | $0.2462 | n/a | 1 | Sep 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $4 | $27.66 | n/a | 1 | Aug 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $5 | $4.65 | n/a | 1 | Jun 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $9 | $3.51 | n/a | 1 | May 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $36 | $5.34 | n/a | 1 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $24 | $13.65 | n/a | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $13 | $1.27 | n/a | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $6 | $0.871 | n/a | 1 | Dec 17, 2024 |
Turn Therapeutics
Sep 24, 2026
Initiated Coverage: Buy
Price Target: $24
Current: $12.00
Upside: +100.00%
Genelux
Sep 16, 2026
Initiated Coverage: Buy
Price Target: $18
Current: $2.56
Upside: +603.13%
Faeth Therapeutics
Sep 14, 2026
Initiated Coverage: Buy
Price Target: $59
Current: $26.03
Upside: +126.66%
Adlai Nortye Group
Sep 8, 2026
Initiated Coverage: Buy
Price Target: $49
Current: $15.62
Upside: +213.70%
Eloxx Pharmaceuticals
Aug 20, 2026
Initiated Coverage: Buy
Price Target: $38
Current: $13.74
Upside: +176.56%
Polaryx Therapeutics
Jul 27, 2026
Initiated Coverage: Buy
Price Target: $7
Current: $2.00
Upside: +250.00%
Quoin Pharmaceuticals
May 4, 2026
Initiated Coverage: Buy
Price Target: $30
Current: $4.50
Upside: +566.67%
Acumen Pharmaceuticals
Dec 17, 2025
Initiated Coverage: Buy
Price Target: $6
Current: $2.14
Upside: +180.37%
Palvella Therapeutics
Dec 15, 2025
Reiterated: Buy
Price Target: $49 → $212
Current: $138.77
Upside: +52.77%
InflaRx
Nov 10, 2025
Reiterated: Buy
Price Target: $24
Current: $1.60
Upside: +1,400.00%
Nov 5, 2025
Initiated Coverage: Buy
Price Target: $19
Current: $4.11
Upside: +362.29%
Oct 14, 2025
Initiated Coverage: Buy
Price Target: $4.00
Current: $0.44
Upside: +819.54%
Sep 15, 2025
Downgraded: Hold
Price Target: $1
Current: $0.2462
Upside: n/a
Aug 25, 2025
Initiated Coverage: Buy
Price Target: $4
Current: $27.66
Upside: n/a
Jun 17, 2025
Initiated Coverage: Buy
Price Target: $5
Current: $4.65
Upside: n/a
May 23, 2025
Initiated Coverage: Buy
Price Target: $9
Current: $3.51
Upside: n/a
May 1, 2025
Initiated Coverage: Buy
Price Target: $36
Current: $5.34
Upside: n/a
Dec 17, 2024
Initiated Coverage: Buy
Price Target: $24
Current: $13.65
Upside: n/a
Dec 17, 2024
Initiated Coverage: Buy
Price Target: $13
Current: $1.27
Upside: n/a
Dec 17, 2024
Initiated Coverage: Buy
Price Target: $6
Current: $0.871
Upside: n/a